These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31488084)

  • 21. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conditional cash transfers to retain rural Kenyan women in the continuum of care during pregnancy, birth and the postnatal period: protocol for a cluster randomized controlled trial.
    Ochieng CA; Haghparast-Bidgoli H; Batura N; Odhiambo A; Shannon G; Copas A; Palmer T; Dickin S; Noel S; Fielding M; Onyango S; Odera S; Eleveld A; Mwaki A; Vanhuyse F; Skordis J
    Trials; 2019 Mar; 20(1):152. PubMed ID: 30823886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Patient Remote Intervention and Symptom Management System (PRISMS) - a Telehealth- mediated intervention enabling real-time monitoring of chemotherapy side-effects in patients with haematological malignancies: study protocol for a randomised controlled trial.
    Breen S; Ritchie D; Schofield P; Hsueh YS; Gough K; Santamaria N; Kamateros R; Maguire R; Kearney N; Aranda S
    Trials; 2015 Oct; 16():472. PubMed ID: 26481873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial.
    de Boniface J; Altena R; Haddad Ringborg C; Bolam KA; Wengström Y
    PLoS One; 2022; 17(10):e0274804. PubMed ID: 36227931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).
    Maguire R; McCann L; Kotronoulas G; Kearney N; Ream E; Armes J; Patiraki E; Furlong E; Fox P; Gaiger A; McCrone P; Berg G; Miaskowski C; Cardone A; Orr D; Flowerday A; Katsaragakis S; Darley A; Lubowitzki S; Harris J; Skene S; Miller M; Moore M; Lewis L; DeSouza N; Donnan PT
    BMJ; 2021 Jul; 374():n1647. PubMed ID: 34289996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Evaluating patient satisfaction and cost-effectiveness of a reduced follow-up schedule: study protocol of a randomized controlled trial.
    Ezendam NPM; de Rooij BH; Kruitwagen RFPM; Creutzberg CL; van Loon I; Boll D; Vos MC; van de Poll-Franse LV
    Trials; 2018 Apr; 19(1):227. PubMed ID: 29661218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data.
    Enright KA; Taback N; Powis ML; Gonzalez A; Yun L; Sutradhar R; Trudeau ME; Booth CM; Krzyzanowska MK
    J Clin Oncol; 2017 Oct; 35(28):3207-3214. PubMed ID: 28682683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
    Wilson BJ; Torrance N; Mollison J; Wordsworth S; Gray JR; Haites NE; Grant A; Campbell MK; Miedyzbrodzka Z; Clarke A; Watson MS; Douglas A
    Health Technol Assess; 2005 Feb; 9(3):iii-iv, 1-126. PubMed ID: 15694064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of Nurse-Led Supportive Care Program on Quality of Life in Women with Breast Cancer Receiving Adjuvant Chemotherapy: A Randomized Controlled Pilot Study.
    Yazicioglu Kucuk B; Zorba Bahceli P
    Semin Oncol Nurs; 2024 Apr; 40(2):151609. PubMed ID: 38433074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN).
    Bauer A; Vordermark D; Seufferlein T; Schmoll HJ; Dralle H; Mau W; Unverzagt S; Boese S; Fach EM; Landenberger M
    BMC Cancer; 2015 Dec; 15():997. PubMed ID: 26694748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study protocol for a controlled trial of an eHealth system utilising patient reported outcome measures for personalised treatment and care: PROMPT-Care 2.0.
    Girgis A; Durcinoska I; Gerges M; Kaadan N; Arnold A; Descallar J; Delaney GP;
    BMC Cancer; 2018 Aug; 18(1):845. PubMed ID: 30139331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
    Mortimer JE; Waliany S; Dieli-Conwright CM; Patel SK; Hurria A; Chao J; Tiep B; Behrendt CE
    Cancer; 2017 May; 123(10):1810-1816. PubMed ID: 28061004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can Chemotherapy-Related Acute Care Visits Be Accurately Identified in Administrative Data?
    Krzyzanowska MK; Enright K; Moineddin R; Yun L; Powis M; Ghannam M; Grunfeld E
    J Oncol Pract; 2018 Jan; 14(1):e51-e58. PubMed ID: 29155611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A complex nursing intervention of complementary and alternative medicine (CAM) to increase quality of life in patients with breast and gynecologic cancer undergoing chemotherapy: study protocol for a partially randomized patient preference trial.
    Klafke N; Mahler C; von Hagens C; Rochon J; Schneeweiss A; Müller A; Salize HJ; Joos S
    Trials; 2015 Feb; 16():51. PubMed ID: 25887713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant chemotherapy in early breast cancer.
    Ejlertsen B
    Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.